Ruiz, Maria Julia, Siracusano, Gabriel, Cottignies-Calamarte, Andréa, Tudor, Daniela, Real, Fernando, Zhu, Aiwei, Pastori, Claudia, Capron, Claude, Rosenberg, Arielle R., Temperton, Nigel J., and others. (2022) Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis. Frontiers in Immunology, 13 . ISSN 1664-3224. (doi:10.3389/fimmu.2022.842468) (KAR id:99236)
|
PDF
Publisher pdf
Language: English |
|
|
Download this file (PDF/10MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.3389/fimmu.2022.842468 |
|
Abstract
The role of the mucosal pulmonary antibody response in coronavirus disease 2019 (COVID-19) outcome remains unclear. Here, we found that in bronchoalveolar lavage (BAL) samples from 48 patients with severe COVID-19-infected with the ancestral Wuhan virus, mucosal IgG and IgA specific for S1, receptor-binding domain (RBD), S2, and nucleocapsid protein (NP) emerged in BAL containing viruses early in infection and persist after virus elimination, with more IgA than IgG for all antigens tested. Furthermore, spike-IgA and spike-IgG immune complexes were detected in BAL, especially when the lung virus has been cleared. BAL IgG and IgA recognized the four main RBD variants. BAL neutralizing titers were higher early in COVID-19 when virus replicates in the lung than later in infection after viral clearance. Patients with fatal COVID-19, in contrast to survivors, developed higher levels of mucosal spike-specific IgA than IgG but lost neutralizing activities over time and had reduced IL-1β in the lung. Altogether, mucosal spike and NP-specific IgG and S1-specific IgA persisting after lung severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance and low pulmonary IL-1β correlate with COVID-19 fatal outcome. Thus, mucosal SARS-CoV-2-specific antibodies may have adverse functions in addition to protective neutralization.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.3389/fimmu.2022.842468 |
| Subjects: | Q Science > QR Microbiology > QR355 Virology |
| Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
| Funders: | Wellcome Trust (https://ror.org/029chgv08) |
| Depositing User: | Nigel Temperton |
| Date Deposited: | 18 Dec 2022 11:18 UTC |
| Last Modified: | 18 Dec 2022 11:18 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/99236 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Temperton, Nigel J..
| Creator's ORCID: |
 https://orcid.org/0000-0002-7978-3815
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
